losartan has been researched along with Liver Diseases in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Liver Diseases: Pathological processes of the LIVER.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oltulu, F | 1 |
| Buhur, A | 1 |
| Gürel, Ç | 1 |
| Kuşçu, GC | 1 |
| Dağdeviren, M | 1 |
| Karabay Yavaşoğlu, NÜ | 1 |
| Köse, T | 1 |
| Yavaşoğlu, A | 1 |
| Lee, S | 1 |
| Choi, JH | 1 |
| Shin, S | 1 |
| Park, D | 1 |
| Jeon, JH | 1 |
| Choi, BH | 1 |
| Jang, MJ | 1 |
| Joo, SS | 1 |
| Oh, KW | 1 |
| Hong, JT | 1 |
| Suh, KH | 1 |
| Kim, YB | 1 |
3 other studies available for losartan and Liver Diseases
| Article | Year |
|---|---|
Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-κB expressions
Topics: Animals; Antihypertensive Agents; Diabetes Complications; Diabetes Mellitus, Experimental; Liver Dis | 2019 |
Comparative evaluation of the antihypertensive activities of losartan and HM70186 during liver dysfunction.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, | 2009 |
Comparative antihypertensive activities of losartan and HM70186 in rats with hepatic dysfunction.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Carbon Tetra | 2009 |